| Today's Big NewsDec 21, 2022 |
|
Jan 11, 2023 | 2:00pm ET Recent advances in natural language processing (NLP) caused an explosion of practical use cases that have now become viable. This webinar for healthcare & life sciences leaders surveys common NLP applications that are being widely deployed, including real world data extraction from pathology & radiology reports, patient risk adjustment & HCC coding, and more. Register now.
|
|
| By Fraiser Kansteiner Teva, Zydus, Macleods and Amneal are struggling to supply a range of copycat Tamiflu doses in both capsule and powder suspension format, the American Society of Health-System Pharmacists (ASHP) reported in early December. |
|
|
|
By Andrea Park Nearly two years after Philips first publicly raised concerns about the potential breakdown of the polyester-based polyurethane foam found in many of its CPAP and BiPAP machines and other respiratory devices, the company has wrapped up safety tests of some of its machines. |
By Annalee Armstrong Zymeworks executives didn’t want to speak for Jazz Pharmaceuticals about the strength of data from a midstage readout for the biliary tract cancer drug zanidatamab earlier this week. But it didn’t take long for Jazz to speak up loud and clear: We’re in. |
By Kevin Dunleavy Less than a week after the FDA delayed a decision on Merck and AstraZeneca’s Lynparza as a treatment for metastatic castration-resistant prostate cancer (mCRPC), Europe has signed off on its use in the same indication. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
By Heather Landi Going into 2023, be prepared for dealmaking activity to shake up the digital health market, analysts and investors say. And, don't be surprised if some of that M&A involves more disruptive deals from Amazon, CVS or Walgreens. |
By Angus Liu GSK pulled Blenrep's accelerated approval amid an “evolving regulatory environment in the U.S.,” GSK’s oncology development head said. Recent regulatory changes could cause a “massive delay” in cancer drug approvals, but Big Pharma is willing to cooperate with the FDA, SVB Securities' Daina Graybosch said. |
By Andrea Park With a slew of tech upgrades already on the horizon, 2023 could be the year that medtech makers finally close the diabetes management loop once and for all. |
By Conor Hale The hospital of the near-future will employ AI and virtual monitoring to triage patients and help health systems short on staff get their clinicians where they're needed most. |
By Paige Minemyer As the healthcare industry continues to grapple with labor shortages and staffing issues, experts argue pharmacists are an underutilized resource that could play a much greater role in patient care. |
By James Waldron Over a year after Merck & Co. narrowed the scope of its long-standing collaboration with NGM Biopharmaceuticals, the Big Pharma has dropped another raft of potential molecules in the wake of a phase 2 fail. |
By James Waldron Celyad Oncology has been making no secret of its transition away from clinical development and toward a focus on R&D, so perhaps it shouldn’t be a surprise to see the company drop its last remaining clinical asset. |
By Frank Diamond In what it calls a continuous effort to make the healthcare system more transparent, the Biden administration wants all Medicare-certified hospitals to release ownership data. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about this year's class of digital health companies that crossed the $1 billion valuation despite an overall funding slowdown. We also discuss how best to leverage population health management to improve how care is delivered and make it more holistic. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now.
|
|
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
